BIOMAT Database Logo BIOMAT Database Logo

[Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors]. 2010

Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Herlev Hospital, Institut for Inflammationsforskning, IIR7521, Rigshospitalet, DK-2100 København Ø, Denmark.

Treatment of inflammatory bowel disease (IBD) with antibodies against tumour necrosis factor-alpha (TNF) is effective. Not all patients respond, however, and the effect wears off in a considerable fraction of initial responders over time. Individual differences in bioavailability, pharmacokinetics and immunogenicity are now recognized as essential problems in the use of biologicals, and blood measurements of functional anti-TNF antibodies and antibodies against anti-TNF drugs with robust and clinically relevant methods may optimize treatment of IBD through individualized therapeutic regimens.

UI MeSH Term Description Entries
D003424 Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients. Colitis, Granulomatous,Enteritis, Granulomatous,Enteritis, Regional,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,Crohn's Disease,Crohn's Enteritis,Inflammatory Bowel Disease 1,Regional Enteritis,Crohns Disease,Granulomatous Colitis,Granulomatous Enteritis,Regional Ileitides,Regional Ileitis,Terminal Ileitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069285 Infliximab A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Inflectra,Infliximab-abda,Infliximab-dyyb,MAb cA2,Monoclonal Antibody cA2,Remicade,Renflexis,Antibody cA2, Monoclonal,Infliximab abda,Infliximab dyyb,cA2, Monoclonal Antibody
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015212 Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. Bowel Diseases, Inflammatory,Inflammatory Bowel Disease

Related Publications

Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Ocular complications of tumour necrosis factor alpha inhibitors.
March 2020, Clinical & experimental optometry,
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Weight gain with tumour necrosis factor-alpha inhibitors.
April 2005, Internal medicine journal,
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.
November 2018, Rheumatology (Oxford, England),
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Tumour necrosis factor inhibitors.
August 2005, The Medical journal of Australia,
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
November 2009, Acta dermato-venereologica,
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
December 2006, Arthritis and rheumatism,
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Natural inhibitors of tumour necrosis factor-alpha production, secretion and function.
May 2000, Planta medica,
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
August 2006, Rheumatology (Oxford, England),
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.
April 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
Casper Steenholdt, and Mark Ainsworth, and Ole Østergaard Thomsen, and Jørn Brynskov, and Klaus Bendtzen
Possible Paradoxical Photosensitive Psoriasis Induced by Tumour Necrosis Factor-alpha Inhibitors.
December 2019, Acta dermato-venereologica,
Copied contents to your clipboard!